Phase 2 N=74 Guanfacine to Improve Substance Use Outcomes in Women
Substance Use Disorders
Primary: Change in Drug Use With Substance Use Calendar — -6.35; -5.61 days — p=0.08
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=34 Follicular Activation in Poor Responders
Infertility
Primary: Number of Metaphase II (MII) — 4; 2 Oocytes — p=0.302
N/A N=371 Dynamic Coronary Roadmap for Contrast Reduction
Coronary Artery Disease
Primary: Total Percutaneous Coronary Intervention (PCI) Iodinated Contrast Volume — 64.6; 90.8 ml
Phase 2 N=48 A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Adenocarcinoma · Pancreatic Neoplasms · Neoplasm, Glandular
Primary: Maximum Tolerated Dose (MTD) of Gemcitabine. — 500 mg/m^2
Phase 1 N=36 Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube
Healthy Adult Subjects
Primary: Area Under the Concentration Versus Time Curve (AUC) of Edaravone — 2612; 2592; 2657; 2617 ng·h/mL
N/A N=1,241 Promoting Physical Activity in Rural Communities
Physical Activity
Primary: Change in Objective Physical Activity Measured by Accelerometer Measured at Baseline and 18-month Follow-up — 63.46; 96.94; 74.02; 76.13 minutes per week
N/A N=10,069 Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi
Preterm Birth · Periodontal Disease · Caries, Dental
Primary: Rate of Preterm Birth — 878; 549 Participants — p=<0.05
Phase 3 N=27 COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
Heart Failure · Heart Failure, Systolic · Erectile Dysfunction
Primary: Erectile Function Score Using Index of Erectile Function (IIEF-15) — 15.1; 12.2 Scores on a scale — p=0.3432
N/A N=53 Attention, Teleconferencing and Social Anxiety
Social Anxiety Disorder
Primary: Personal Report of Communication Apprehension Questionnaire — 88.06; 87.64; 95.69 score on a scale
N/A N=234 Myeloproliferative Neoplasms: an In-depth Case-control Study
Polycythemia Vera · Essential Thrombocythemia · Primary Myelofibrosis
Primary: Influence of Pre- and Post- Incentives on Participation Rates. — 4; 6; 15; 69 Participants
Phase 1 N=54 A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
Sarcoma
Primary: Area Under the Concentration-time Curve From the Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor — 2752; 3175; 3280; 3342 Nanograms*hour per…
Phase 3 N=104 A Study of OV101 in Individuals With Angelman Syndrome (AS)
Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
Primary: Clinical Global Impressions- Improvement in Angelman Syndrome (CGI-I-AS) Rating at 12 Weeks — 1; 2; 11; 11 Participants
Phase 1 N=18 Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
Asthma
Primary: Maximum Observed Serum Concentration (Cmax) of Tezepelumab — 27.1 microgram per milliliter (mcg/mL)
N/A N=17 Vagus Nerve Stimulation as Treatment for Long Covid
Long COVID · Chronic Fatigue Syndrome
Primary: Number of Participants With Treatment Success — 8 Participants
Phase 1 N=26 A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys
Renal Impairment · Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Mobocertinib and Its Active Metabolites (AP32960 and AP32914) — 17.1; 11.2; 12.2; 7.92 nanograms per milliliter(ng/mL)